{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:47:23Z","timestamp":1789634843539,"version":"4.0.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2556,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1111\/j.1365-2133.2008.08728.x","type":"journal-article","created":{"date-parts":[[2008,7,8]],"date-time":"2008-07-08T19:55:25Z","timestamp":1215546925000},"page":"527-536","source":"Crossref","is-referenced-by-count":71,"title":["Review and expert opinion on prevention and treatment of infliximab-related infusion reactions"],"prefix":"10.1093","volume":"159","author":[{"given":"L.L.A.","family":"Lecluse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Piskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.R.","family":"Mekkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.D.","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"de Rie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB1","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.jaad.2006.07.019","article-title":"Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2)","volume":"56","author":"Graves","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB2","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB3","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial","volume":"51","author":"Gottlieb","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB4","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB5","first-page":"250","article-title":"Monoclonal antibodies, immunogenicity, and associated infusion reactions","volume":"72","author":"Cheifetz","year":"2005","journal-title":"Mt Sinai J Med"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB6","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1572-0241.2003.07457.x","article-title":"The incidence and management of infusion reactions to infliximab: a large center experience","volume":"98","author":"Cheifetz","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB7","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1517\/14712598.6.8.797","article-title":"Infliximab for the treatment of psoriasis","volume":"6","author":"Kleyn","year":"2006","journal-title":"Expert Opin Biol Ther"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB8","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/S0190-9622(03)01143-5","article-title":"Infliximab for psoriasis","volume":"49","author":"Gottlieb","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB9","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1186\/ar2020","article-title":"Predictors of infusion reactions during infliximab treatment in patients with arthritis","volume":"8","author":"Kapetanovic","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00054725-200102000-00005","article-title":"Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn\u2019s disease patients with prior anaphylactic reaction","volume":"7","author":"Puchner","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB11","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1157\/13080935","article-title":"Severe anaphylactic reaction during the second infusion of infliximab in a patient with psoriatic arthritis","volume":"33","author":"Chavez-Lopez","year":"2005","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB12","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1081-1206(10)61797-8","article-title":"A patient\u2019s reaction to infliximab","volume":"90","author":"Domm","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB13","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/rheumatology\/41.6.631","article-title":"Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study","volume":"41","author":"Kiely","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1651-2227.2007.00042.x","article-title":"Severe adverse reactions to infliximab therapy are common in young children with inflammatory bowel disease","volume":"96","author":"Kolho","year":"2007","journal-title":"Acta Paediatr"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB15","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1111\/j.1572-0241.2000.02349.x","article-title":"Severe anaphylactic reaction to infliximab: report of a case","volume":"95","author":"Soykan","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB16","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/00042737-200406000-00018","article-title":"Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case","volume":"16","author":"Stallmach","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clim.2005.07.010","article-title":"Clinical and biological consequences of immunization to infliximab in pediatric Crohn\u2019s disease","volume":"118","author":"Candon","year":"2006","journal-title":"Clin Immunol"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB18","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1365-2036.2006.03026.x","article-title":"Successful induction of tolerance to infliximab in patients with Crohn\u2019s disease and prior severe infusion reactions","volume":"24","author":"Duburque","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB19","first-page":"1307","article-title":"Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology","volume":"33","author":"Lequerre","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB20","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/1529-0131(200107)44:7<1717::AID-ART299>3.0.CO;2-C","article-title":"Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab)","volume":"44","author":"D\u2019Arcy","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB21","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/j.1572-0241.2002.05784.x","article-title":"Infliximab retreatment in adults and children with Crohn\u2019s disease: risk factors for the development of delayed severe systemic reaction","volume":"97","author":"Kugathasan","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/art.21671","article-title":"Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis","volume":"54","author":"Wolbink","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB23","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB24","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/gast.2003.50145","article-title":"Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn\u2019s disease: a randomized controlled trial","volume":"124","author":"Farrell","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB25","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","article-title":"Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn\u2019s disease","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaad.2006.07.017","article-title":"A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1\u2003year in the treatment of moderate-to-severe plaque psoriasis","volume":"56","author":"Menter","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB27","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1136\/ard.2005.037499","article-title":"Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis","volume":"64","author":"Sany","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB28","first-page":"1912","article-title":"Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number","volume":"31","author":"Wasserman","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB29","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn\u2019s disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB30","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/art.22214","article-title":"Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab","volume":"54","author":"Bendtzen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB31","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1046\/j.1365-2036.2003.01411.x","article-title":"Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model","volume":"17","author":"Crandall","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB32","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1136\/ard.2007.070771","article-title":"Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis","volume":"66","author":"Augustsson","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB33","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/00054725-200411000-00008","article-title":"Efficacy and tolerance of infliximab in children and adolescents with Crohn\u2019s disease","volume":"10","author":"Lamireau","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB34","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/00005176-200405000-00008","article-title":"Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab","volume":"38","author":"Miele","year":"2004","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB35","first-page":"1411","article-title":"Reactions to infliximab in patients with rheumatoid arthritis","volume":"32","author":"Prupas","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB36","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1572-0241.2001.03612.x","article-title":"Infliximab for Crohn\u2019s disease in clinical practice at the Mayo Clinic: the first 100 patients","volume":"96","author":"Ricart","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000080075","article-title":"Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital","volume":"70","author":"Seiderer","year":"2004","journal-title":"Digestion"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB38","first-page":"667","article-title":"Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis","volume":"29","author":"Shergy","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB39","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2165\/00003495-200464160-00004","article-title":"Managing immunogenic responses to infliximab: treatment implications for patients with Crohn\u2019s disease","volume":"64","author":"Han","year":"2004","journal-title":"Drugs"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB40","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1111\/j.1572-0241.2002.07093.x","article-title":"Infliximab in the treatment of Crohn\u2019s disease: a user\u2019s guide for clinicians","volume":"97","author":"Sandborn","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB41","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/01.MIB.0000158166.88238.ea","article-title":"Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium","volume":"11","author":"Jacobstein","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohn\u2019s disease: the Mayo clinic experience in 500 patients","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB43","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0761-8425(05)85477-4","article-title":"[Desensitisation to infliximab in patients with Crohn\u2019s disease]","volume":"22","author":"Lelong","year":"2005","journal-title":"Rev Mal Respir"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB44","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1365-2133.2004.06105.x","article-title":"Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab","volume":"151","author":"Chew","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB45","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2008.08728.x-BIB46","first-page":"608","article-title":"Immunomodulators and \u2018on demand\u2019 therapy with infliximab in Crohn\u2019s disease: clinical experience with 400 infusions","volume":"98","author":"Kinney","year":"2003","journal-title":"Am J Gastroenterol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2008.08728.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2008.08728.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T13:41:59Z","timestamp":1676382119000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/159\/3\/527\/6641567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,9]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08728.x","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}